Massachusetts is currently home to 3217 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Lurbinectedin in FET-Fused Tumors
NCT05918640
Recruiting
The purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma.
Gender:
ALL
Ages:
10 years and above
Trial Updated:
03/06/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Pediatric Cancer, Undifferentiated Sarcoma
Register for Updates
Y-90 with Durvalumab/Gem/Cis in Intrahepatic Cholangio
NCT05655949
Recruiting
This trial is designed to study a combination of interventions (chemotherapy, immunotherapy, and radiation) as a potential new treatment for bile duct cancer that cannot be removed with surgery. The specific names of the interventions that will be used are: * Y-90 (a type of radiation microsphere bead) * Durvalumab (a type of immunotherapy) * Gemcitabine (a type of chemotherapy) * Cisplatin (a type of chemotherapy)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Bile Duct Cancer, Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic, Metastatic Intrahepatic Cholangiocarcinoma
Register for Updates
Physical Activity for PLWH and Unhealthy Drinking
NCT05505942
Recruiting
Brief Summary: Alcohol use disorder (AUD) is a significant and costly public health problem that affects one-third of the U.S. population in their lifetime. Specifically, unhealthy alcohol use is common among persons living with HIV (PLWH) and increases the risk of developing negative outcomes. Antiretroviral therapy (ART) has shown increasing life expectancy and decreased HIV-related deaths, leading to a growing older adult HIV population. Yet, HIV accelerates the aging process and increases th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: Boston University, Department of Medicine, remote research, Boston, Massachusetts
Conditions: HIV, Physical Inactivity, Unhealthy Alcohol Use
Register for Updates
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
NCT04301765
Recruiting
This is a large randomized, double-blind, placebo-controlled trial to determine the efficacy of testosterone replacement on cancer-related fatigue in older men with solid or hematologic (blood) cancer who report fatigue and have low testosterone levels.
Gender:
MALE
Ages:
55 years and above
Trial Updated:
03/06/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Hypogonadism, Male, Cancer, Fatigue
Register for Updates
Testosterone Replacement in Male Cancer Survivors with Fatigue and Low Testosterone
NCT04049331
Recruiting
The overall goal of this study is to evaluate the effect of a testosterone drug called Depo-Testosterone (or 'testosterone cypionate'), an FDA-approved drug for improving fatigue, sexual function, quality of life, body composition, muscle strength, and physical activity in young cancer survivors who report fatigue and have low testosterone. Main hypothesis is that Testosterone administration in young male cancer survivors who are in remission for at least 1 year, report cancer-related fatigue an... Read More
Gender:
MALE
Ages:
Between 18 years and 54 years
Trial Updated:
03/06/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Hypogonadism, Male, Fatigue Syndrome, Chronic
Register for Updates
Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients with R/r NHL and R/r B-cell ALL
NCT03666000
Recruiting
This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL and r/r B-cell NHL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
Register for Updates
Assessment of a Physio-neuro Platform (SynPhNe) for Home-based Retraining of Hand Function in Stroke Survivors
NCT02896348
Recruiting
The goal of this study is to: 1. Assess the usability of the SynPhNe device in a home environment. 2. Evaluate the efficacy of the SynPhNe home use device to improve motor hand function in chronic stroke subjects as compared to standard care alone.
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
03/06/2025
Locations: Spaulding Rehabilitation Hospital, Boston, Massachusetts
Conditions: Stroke, Hemiparesis
Register for Updates
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
NCT06602232
Recruiting
This is a multi-center, parallel-group, open-label, randomized, Phase 1b study to explore the safety, clinical activity, pharmacokinetics and pharmacodynamics of DR-01 in adults with Alopecia Areata or Vitiligo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: Dren Investigational Site, Worcester, Massachusetts
Conditions: Alopecia Areata, Vitiligo
Register for Updates
BMT-CARE: Psychosocial Intervention for Transplant Caregivers
NCT06472089
Recruiting
The goal of this study is to evaluate whether a psychological intervention (BMT-CARE) is effective at improving the quality of life in caregivers and patients treated with hematopoietic cell transplant compared to usual care, and to identify critical facilitators and barriers for BMT-CARE implementation and adoption.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Bone Marrow Transplant Complications, Hematologic Malignancy
Register for Updates
Low-Dose Short-Term Ketorolac to Reduce Chronic Opioid Use in Orthopaedic Polytrauma Patients
NCT06201676
Recruiting
The goal of this randomized clinical trial is to learn if the use of a low-dose nonsteroidal anti-inflammatory drug (NSAID), ketorolac, reduces the rate of chronic opioid use in orthopaedic polytrauma patients. The main questions this study aims to answer are: 1. Are patients who are given scheduled ketorolac during the first five hospital days less likely to develop chronic opioid use at 6 months after injury compared to patients who receive placebo? 2. Does scheduled ketorolac during the firs... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/05/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Orthopaedic Polytrauma, Chronic Opioid Use
Register for Updates
Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant
NCT05579639
Recruiting
Bloodstream infections (BSI) caused by bacteria translocating across injured oral mucosa are a significant cause of morbidity and mortality in patients undergoing stem cell transplantation (SCT). Unfortunately, there are currently no known strategies to prevent these BSI in this vulnerable population. The investigators will conduct a randomized, double-blind, placebo-controlled trial at three institutions to evaluate the effectiveness of twice daily intraoral xylitol-wipe application on reducing... Read More
Gender:
ALL
Ages:
Between 4 months and 25 years
Trial Updated:
03/05/2025
Locations: Dana-Farber/Boston Children's, Boston, Massachusetts
Conditions: Allogeneic Stem Cell Transplantation
Register for Updates
Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression - R33
NCT05573074
Recruiting
The purpose of this research study is to determine if application of near infrared energy to the forehead can change blood flow in the brains of people with depression. Near infrared energy is like light but is not visible to the human eye.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/05/2025
Locations: Harvard Medical School, Boston, Massachusetts
Conditions: Major Depressive Disorder
Register for Updates